NCT03124524 - Treatment Choice in Primary Dysmenorrhea | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2015

Primary Completion Date

September 20, 2016

Study Completion Date

October 10, 2016

Conditions

Primary Dysmenorrhea

Interventions

DRUG

estradiol valerate/dienogest

oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively

DRUG

ethinylestradiol and drospirenone

oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)

All Listed Sponsors

lead

Adana Numune Training and Research Hospital

OTHER_GOV